{
    "clinical_study": {
        "@rank": "144568", 
        "acronym": "no", 
        "arm_group": [
            {
                "arm_group_label": "BIO 25 (food supplements)twice a day for 8 weeks", 
                "arm_group_type": "Active Comparator", 
                "description": "BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule."
            }, 
            {
                "arm_group_label": "Placebo twice a day for 8 weeks", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo twice a day for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to examine whether probiotics given to hypercholesterolemic\n      patients treated with statins, would further decrease LDL-Cholesterol levels.\n\n      The secondary objective is to examine whether adding of probiotics to statins would decrease\n      fasting glucose levels and glycolysated hemoglobin"
        }, 
        "brief_title": "Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1) Patients on maximal tolerated dose of conventional statins treated for at least eight\n        weeks on simvastatin 40, pravastatin 40, atorvastatin 40-80 or rosuvastatin 20-40 mg, who\n        failed to achieve target values of LDL-cholesterol according to the European Socety\n        Cardiology guidelines 2012.\n\n        Exclusion Criteria:\n\n          1. Patients on chronic antibiotic treatment\n\n          2. Patients with immune disorders\n\n          3. Patients who are not receiving maximal dose of statin therapy or receive combination\n             of statins for dyslipidemia.\n\n          4. Patients who experienced myocardial infarction within less than two months.\n\n          5. Patients who consume probiotics."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849185", 
            "org_study_id": "mmc120213ctil"
        }, 
        "intervention": {
            "arm_group_label": [
                "BIO 25 (food supplements)twice a day for 8 weeks", 
                "Placebo twice a day for 8 weeks"
            ], 
            "intervention_name": "Food supplement", 
            "intervention_type": "Other", 
            "other_name": "BIO-25"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hypercholesterolemia", 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kfar Saba", 
                    "country": "Israel", 
                    "zip": "44281"
                }, 
                "name": "Division of Cardiology Meir MC"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "morris.mosseri@clalit.org.il", 
            "last_name": "Morris Mosseri, MD", 
            "phone": "97297472587"
        }, 
        "overall_contact_backup": {
            "email": "tatiana.berlin@clalit.org.il", 
            "last_name": "Tatiana Berlin, MD", 
            "phone": "97297472587"
        }, 
        "overall_official": {
            "affiliation": "Division of Cardiology Meir MC", 
            "last_name": "Tatiana Berlin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: clalit health services", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to examine whether probiotics given to hypercholesterolemic patients treated with statins, would further decrease LDL-Cholesterol levels.", 
            "measure": "LDL-Cholesterol levels.", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849185"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objective is to examine whether adding of probiotics to statins would decrease fasting glucose levels and glycosylated  hemoglobin", 
            "measure": "Hemoglobin A1C", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}